S112: TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FINAL ANALYSES FROM THE ELIANA STUDY
Main Authors: | S. Rives, S. L. Maude, H. Hiramatsu, A. Baruchel, P. Bader, H. Bittencourt, J. Buechner, T. Laetsch, B. De Moerloose, M. Qayed, H. E. Stefanski, K. L. Davis, P. L. Martin, E. Nemecek, C. Peters, G. Yanik, A. Balduzzi, N. Boissel, S. L. Khaw, J. Krueger, J. Levine, S. Davies, G. D. Myers, A. Yeo, D. O’Donovan, R. Ramos, M. Pulsipher, S. Grupp |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843344.19780.98 |
Similar Items
-
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
by: Rajen Mody, et al.
Published: (2021-08-01) -
S255: EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDY
by: V. Minard-Colin, et al.
Published: (2022-06-01) -
Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells
by: Andrew M. Stein, et al.
Published: (2019-05-01) -
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
by: Vairy S, et al.
Published: (2018-11-01) -
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patternsResearch in context
by: Valentin Barsan, et al.
Published: (2023-11-01)